Get startedLog in
    Picture of Novo Nordisk A/S logo

    NOVO B — Novo Nordisk A/S News Story

    0.000.00%
    dk flag iconLast trade - 00:00
    HealthcareSpeculativeLarge CapNeutral
    All News

    Novo Nordisk says Ozempic shows lower risk of cardiovascular events compared to Eli Lilly's Mounjaro

    Picture of Novo Nordisk A/S logoNovo Nordisk A/S
    29/09/2026 11:28
    Novo Nordisk says Ozempic shows lower risk of cardiovascular events compared to Eli Lilly's Mounjaro
    COPENHAGEN, Sept 29 (Reuters) - Novo Nordisk NOVOb.CO said on Tuesday a real-world study found that adults with type 2 diabetes who escalated their dose of diabetes drug Ozempic to 2 milligrams (mg) from 1 mg had a lower risk of major cardiovascular events compared to those who switched to Eli Lilly's Mounjaro. 

    (Reporting by Louise Rasmussen, editing by Stine Jacobsen)
    ((Louisebreusch.rasmussen@tr.com; +45 21 27 97 79;))

    Recent news on Novo Nordisk A/S

    See all news